Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to ...

Educating physicians about PSA reduction goals may increase the number of patients with mCSPC receiving first-line treatment ...

Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform ...

Aptevo Therapeutics (APVO) announced two additional frontline AML patients have achieved remission within 30 days of treatment in the Company’s ...

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform ...

outperforming the doublet remission rate from a venetoclax + azacitidine-only study of 66%. Additionally, the frontline patient triplet therapy complete remission (CR) rate of 70% outperforms the ...

Dr. Dawson calls this "doublet therapy." And "triplet therapy" is ADT, another form of hormone therapy, and chemotherapy — usually docetaxel, she says. "The drugs approved to be added to ADT ...

This outperforms the doublet remission* rate from a venetoclax + azacitidine only study, of 66%. Additionally, the frontline patient triplet therapy CR rate of 70% outperforms the CR rate from a ...